Press Room

RDD 2021

Start
Tuesday, May 04, 2021 - 00:00
End
Friday, May 07, 2021 - 00:00
Location: online
Continuous Manufacturing Drug Product Commercial Supply | Hovione

If you would like to find more about Hovione's full range of inhalation development servicesparticle engineering and development by design schedule a meeting with us.

 

steve-landelius-photo

Steven Landelius

Business Development Manager



 

 

Schedule a meeting button | Hovione













From May 4-7, do not miss Hovione's Scientists Presentations at RDD 2021 virtual conference.



 

WORKSHOP

PRESENTATION

Fully Integrated DPI Development – From API To Device

João Pereira and Beatriz Noriega Fernandes

 

What will you learn?
  • How to choose a suitable API formulation
  • How to select the right particle engineering technology
  • Novel techniques for inhalation products characterization
  • Advanced solutions for inhalation platforms

POSTERS

Comparison of Two Drug Micronization Methods Using Multiple Physiochemical Characterization Techniques

Sara Perico

 

Understanding Particle Friability Through Solid State Characterization

Ruben Chaves

ABSTRACTS

Amorphous Solid Dispersions for Nasal Delivery: Development, Characterization and Performance Studies

Patricia Henriques

 

Our experts are available to listen and understand your projects. Together we can speed up your Inhalation drug development, with less regulatory hurdles, less time, and less costs.





 

 
Drug Product Facility in Portugal | Hovione

 

 

Hovione Inhalation Development Virtual Tour (click on the image to watch video)

Meet Eunice Costa, Hovione’s group leader for Inhalation Development and visit the site where all the team sits together.











 

 

Also in the Press Room

See All

Integrated approach simplifies development, reduces risk, and supports scalable manufacturing. Hovione and Industrial Design Consultancy Ltd.’s (IDC) lead single-use nasal dry powder device is now available for commercial partnerships. Hovione and IDC have completed the device design and established initial device manufacturing and supply capability, enabling pharmaceutical partners to leverage existing capsule filling infrastructure. This approach simplifies development, reduces cost and risk, and helps shorten timelines to the clinic and commercialization. “This milestone marks an important step in the evolution of our collaboration with IDC — from device innovation to a fully integrated intranasal drug delivery platform,” said Márcio Temtem, Ph.D., Vice President, Strategic Business Management, Hovione. “As the industry looks for faster, more reliable ways to bring complex therapies to patients, integration becomes critical. By bringing together nasal particle engineering science, formulation manufacturing and filling, and device technologies into a single offering, we enable a more seamless and predictable development journey, accelerating the path to market for intranasal therapies.” The nasal delivery device enables broad and targeted nasal deposition flexibility while delivering maximum usability and reliability. With a patented design and manufacturing process established, the platform is available for partnering with pharmaceutical companies on an exclusive basis as part of Hovione’s integrated offering for inhalation and nasal drug development and manufacturing. Additionally, IDC’s Managing Director, Stephen Knowles Ph.D., said the companies are now “well-advanced” with the development of a multi-use device to support an even wider range of therapies and patient needs. Read the full article at ContractPharma.com    

Press Clipping

Hovione, IDC Launch Intranasal Drug Delivery Platform

May 07, 2026